Tuesday, July 02, 2019 4:18:43 PM
Bio,
One thing is for sure, beyond a reasonable doubt, is that Missling and Hampel have been tethered to each other since Hampel appointment at Eisai. The Saturday night tweet proves that to be true because there is data driving that communication, which we just don't know what data that is exactly. It's his study which for all intent and purposes is being peer reviewed, at least that is the impression I get by the way he speaks of 273 and the findings of the study.
So Eisai gives him title "VP Global Medical Affairs" but that same person is still connected to Anavex. The really speculative part of my brain is thinking Eisai has been courting Anavex, and Hampels hire is part of that whole mechanism that Eisai is using to eventually run the programs.
Hampel is precision Medicine and Anavex is precision medicine, so why hasn't this happened already boggles my mind.
To your question, I think Missling and Hampel work well together so it seems so natural for Eisai to connect with Anavex now. It's like a quarterback being reunited with his star receiver after being separated.
I don't think Eisai hired Hampel to object to his desire to potentially partner with Anavex, which is why I think it happens!
One thing is for sure, beyond a reasonable doubt, is that Missling and Hampel have been tethered to each other since Hampel appointment at Eisai. The Saturday night tweet proves that to be true because there is data driving that communication, which we just don't know what data that is exactly. It's his study which for all intent and purposes is being peer reviewed, at least that is the impression I get by the way he speaks of 273 and the findings of the study.
So Eisai gives him title "VP Global Medical Affairs" but that same person is still connected to Anavex. The really speculative part of my brain is thinking Eisai has been courting Anavex, and Hampels hire is part of that whole mechanism that Eisai is using to eventually run the programs.
Hampel is precision Medicine and Anavex is precision medicine, so why hasn't this happened already boggles my mind.
To your question, I think Missling and Hampel work well together so it seems so natural for Eisai to connect with Anavex now. It's like a quarterback being reunited with his star receiver after being separated.
I don't think Eisai hired Hampel to object to his desire to potentially partner with Anavex, which is why I think it happens!
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
